Core Viewpoint - Aldeyra Therapeutics, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its drug candidate reproxalap during clinical trials [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from November 3, 2023, to March 16, 2026, with a deadline for participation set for May 29, 2026 [2]. - The complaint alleges that Aldeyra's positive statements about its clinical trials were unreliable and that the results of reproxalap were inconsistent [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although such an appointment is not necessary to recover losses [2][3].

Core Viewpoint - Rowley Law PLLC is investigating potential securities law violations related to the proposed merger between Equitable Holdings, Inc. and Corebridge Financial, Inc. [1] Summary by Relevant Sections - **Merger Details**: Equitable Holdings stockholders will receive 1.55516 shares of the combined company's common stock for each share they hold. Post-merger, they will own approximately 49% of the combined entity. The transaction is anticipated to close by the end of 2026 [1]. - **Legal Investigation**: The investigation by Rowley Law PLLC focuses on the actions of Equitable Holdings and its board of directors regarding the merger, suggesting potential legal implications for the company [1].

Core Viewpoint - Gemini Space Station, Inc. is facing a class action lawsuit for violations of federal securities laws, with allegations of making false and misleading statements regarding its crypto platform and international expansion plans [1][2]. Group 1: Lawsuit Details - The class period for the lawsuit is from September 12, 2025, the date of Gemini's initial public offering (IPO), to February 17, 2026 [2]. - The lawsuit claims that Gemini overstated the viability of its crypto platform and misled investors about growth prospects from international expansion [2]. Group 2: Investor Participation - Shareholders who purchased shares during the class period are encouraged to contact the DJS Law Group for potential lead plaintiff appointments, although such an appointment is not necessary to participate in any recovery [2][3]. Group 3: Legal Representation - DJS Law Group specializes in securities class actions and corporate governance litigation, focusing on enhancing investor returns through advocacy [4].

Core Viewpoint - Wealthfront Corporation is under investigation for potential violations of federal securities laws, particularly concerning misleading statements made during its IPO process [1][3]. Group 1: Company Overview - Wealthfront is an online financial advisor that utilizes automated tools to provide investment and financial advice [2]. - The company completed its initial public offering (IPO) on December 12, 2025, offering over 34 million shares at a price of $14.00 per share [2]. Group 2: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP focuses on whether Wealthfront made false and misleading statements to investors, especially in the IPO offering materials [3]. - The investigation is prompted by significant changes in the company's financial performance following its IPO [3]. Group 3: Financial Performance and Stock Impact - On January 12, 2026, Wealthfront reported its first quarterly results as a public company, revealing net deposit outflows of $208 million, a significant decline from the $874 million inflows during the same period the previous year [4]. - Following the earnings report, Wealthfront's stock price dropped by $2.12 per share, nearly 17%, from $12.59 to $10.47 per share [4]. - CEO David Fortunato attributed the decline in deposits to falling interest rates and highlighted the strategic importance of the company's new home-lending business [4].

Core Viewpoint - Disc Medicine, Inc. is under investigation for potential violations of federal securities laws following the FDA's issuance of a Complete Response Letter (CRL) for its lead therapeutic candidate, bitopertin, which delays approval and impacts revenue projections [1][2][3][4][5]. Group 1: FDA Response and Impact - On February 13, 2026, the FDA issued a CRL for bitopertin, indicating that the drug application cannot be approved in its current form and requires additional data submissions [2]. - Bitopertin was positioned as a transformative therapy for approximately 4,000 Erythropoietic protoporphyria (EPP) patients, but the CRL delays potential approval until at least 2027, affecting near-term revenue expectations [3]. - Following the CRL announcement, Disc Medicine's shares fell by 21.9%, reflecting market expectations for a favorable FDA outcome based on prior communications [4]. Group 2: Investigation Focus - The investigation by Levi & Korsinsky is centered on whether Disc Medicine and its executives made misleading statements regarding the regulatory prospects of the bitopertin program, not fully disclosing the risks faced during interactions with the FDA prior to the CRL [5].

Core Viewpoint - Hub Group Inc. is under investigation for potential violations of federal securities laws, specifically regarding misrepresentation of transportation costs and accounts payable for the first nine months of 2025 [1][2]. Group 1: Investigation Details - Bleichmar Fonti & Auld LLP is leading the investigation into Hub Group for possible misrepresentation of financial data [1]. - The investigation focuses on whether Hub Group inaccurately reported its purchased transportation costs and accounts payable [2]. Group 2: Stock Performance - Hub Group announced a delay in the release of its fourth quarter and full year 2025 financial results, along with a restatement of its financial statements for the first three quarters of 2025 due to an error in reporting transportation costs [3]. - Following this announcement, Hub Group's stock price fell over 24% during trading on February 6, 2026 [4].

Core Insights - PROCEPT BioRobotics Corporation is under investigation for potential violations of federal securities laws, as announced by Levi & Korsinsky [1] Financial Performance - In the Q3 2025 earnings call, CFO Kevin Waters reaffirmed a revenue target of $325.5 million and maintained average selling prices for handpieces at approximately $3,200 [2] - The company implemented a pricing-discipline initiative that eliminated bulk-purchase discounts, which directly reduced realized average selling prices on its core product line [2] - Actual revenue for Q4 2025 fell short by $17.4 million compared to the guidance, and the FY 2026 revenue guidance of $410 million to $430 million was also below analyst consensus, leading to a 15% drop in stock value in a single session [3]

Core Insights - Xponential Fitness is under investigation for potential violations of federal securities laws following a significant financial loss and revenue decline projection [1][2] - The company reported a larger-than-expected loss for Q4 and full year 2025, with a projected 16% revenue decline in 2026 [2] - Xponential has agreed to pay $17 million over 12 months and finalized a $22.75 million settlement with over 500 franchisees due to allegations of misleading financial projections [2] Financial Performance - For Q4 and full year 2025, Xponential reported a much larger-than-expected loss [2] - The company projects a 16% decline in revenue for 2026 [2] - Following the financial report, Xponential's stock price fell by $3.79 per share, or 47.08%, closing at $4.26 per share on February 27, 2026 [3] Legal and Settlement Issues - Xponential has agreed to a $17 million payment over a 12-month period related to the investigation [2] - The company finalized a $22.75 million settlement to be paid over 35 months with over 500 current and former franchisees [2] - The allegations involve misleading franchisees regarding financial projections and the health of certain fitness studios [2]

Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit for securities law violations, specifically for making false and misleading statements regarding its production capabilities and operational performance [1]. Group 1: Lawsuit Details - The class action lawsuit is based on violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1]. - The class period for the lawsuit is from November 5, 2025, to February 26, 2026, with a deadline for participation set for May 5, 2026 [1]. - The complaint alleges that Eos Energy was unable to achieve the necessary ramp in production to meet its own guidance, indicating significant operational issues [1]. Group 2: Company Performance Issues - Eos Energy reportedly experienced battery downtime that was significantly higher than both its forecasts and industry norms, contributing to the misleading nature of its public statements [1]. - The lawsuit claims that the company's public disclosures were false and materially misleading throughout the class period, impacting shareholder trust and investment [1].

Core Viewpoint - Inovio Pharmaceuticals, Inc. is facing a class action lawsuit for alleged securities law violations, with claims that the company made materially false and misleading statements regarding its manufacturing processes and regulatory prospects for its lead product candidate, INO-3107 [1]. Group 1: Allegations - The lawsuit alleges that Inovio's manufacturing for the CELLECTRA device was deficient [1]. - It is claimed that Inovio is unlikely to submit its lead product candidate, INO-3107 BLA, to the FDA by the second half of 2024 [1]. - The company reportedly lacked sufficient information to justify INO-3107's eligibility for FDA accelerated approval or priority review [1]. - Consequently, the overall regulatory and commercial prospects of INO-3107 were overstated [1]. - As a result, the defendants' public statements were materially false and misleading throughout the relevant period [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as October 10, 2023, to December 26, 2025 [1]. - Shareholders are encouraged to register for the class action by April 7, 2026, to discuss their rights and potential recovery [1]. - There is no cost or obligation for shareholders to participate in the case [1].